NASDAQ · Biotechnology

Ikena Oncology, Inc. (IKNA) Stock

$17.16 +1152.55% NASDAQ: IKNA Healthcare

Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology.

Valuation

MetricValue
Price$17.16
Market Cap$718.82M
P/E Ratio-22.36
P/B Ratio1559.96
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$23.28
52-Week Low$1.36
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-46.58%
ROA-38.75%
ROCE-38.24%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio18.39

Annual Financials (USD)

Metric20212022202320242025
Revenue$31.0M$16.0M$9.0M$0$0
Operating Profit$-34.0M$-71.0M$-75.0M$-55.0M$-48.0M
Net Profit$-34.0M$-69.0M$-68.0M$-49.0M$-52.0M
EPS$-0.95$-1.90$-1.63$-1.02$0.00
Op Margin-110.2%-454.0%-823.3%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$248.0M$172.0M$192.0M$142.0M$83.0M
Total Liabilities$40.0M$25.0M$22.0M$16.0M$7.0M
Cash$232.0M$60.0M$120.0M$39.0M$35.0M
Borrowings$7.0M$6.0M$11.0M$8.0M$0

Latest News

RSP Nears $100 Billion as Equal Weight Finally Has Its Year etf.com · Jul 31, 2026 Dow Jones Futures: Apple, Amazon Diverge Late; What To Do After AI Stocks Surge Investor's Business Daily · Jul 31, 2026 South Korea’s Kospi index jumps more than 13%, tracking Wall Street gains, on a surge of chipmaking stocks Associated Press · Jul 31, 2026 Archer Aviation vs. MP Materials: Which Stock Is a Better Buy in 2026? Motley Fool · Jul 31, 2026 Percheron Therapeutics targets clinical return for HMBD-002 after productive June quarter Proactive · Jul 31, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-60.0M$-74.0M$-80.0M$-46.0M$-48.0M
Investing Cash Flow$-4.0M$-101.0M$64.0M$-35.0M$-6.0M
Financing Cash Flow$1.0M$0$-1.0M$0$135.0M
Net Cash Flow$70.0M$-172.0M$60.0M$-81.0M$82.0M
Free Cash Flow$-62.0M$-76.0M$-80.0M$-46.0M$-48.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA66.01
FCF Yield-7.25%
Quick Ratio18.39
Interest Coverage-44.05
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASLNASLAN Pharmaceuticals Limited $0.60 -14.27% -0.06 $777.12M 0.00%
CDMOAvid Bioservices, Inc. $12.49 +0.00% -5.60 $798.90M 0.00%
CMRXChimerix, Inc. $8.54 +0.00% -8.63 $801.08M 0.00%
EXAIExscientia plc $4.84 — -3.06 $633.18M 0.00%
ICPTIntercept Pharmaceuticals, Inc. $19.00 +0.21% 5.57 $794.69M 0.00%

About Ikena Oncology, Inc.

Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs. The company's leading drug candidate is IK-930, an orally administered small molecule designed to inhibit the transcriptional enhanced associate domain (TEAD) transcription factor, a key component of the Hippo signaling pathway. Ikena is also progressing a portfolio of other investigational therapies, including: A small molecule inhibitor program targeting ERK5 within the RAS signaling pathway. IK-175, an oral compound that inhibits the aryl hydrocarbon receptor. IK-007, an orally delivered, selective antagonist of the EP4 receptor, which is being developed for the treatment of microsatellite stable colorectal cancer. Founded in 2016, the company is based in Boston, Massachusetts.

Ikena Oncology, Inc. is headquartered in US.

Ikena Oncology, Inc. (IKNA) stock trades at $17.16 with a market capitalization of $718.82M. The stock is valued at a price-to-earnings (P/E) ratio of -22.36, price-to-book of 1559.96, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.36 and $23.28, and currently trades 26.3% below its 52-week high.

On profitability, Ikena Oncology, Inc. generates a return on equity (ROE) of -46.58%, return on capital employed of -38.24%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: ikenaoncology.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides